These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19892442)

  • 1. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors.
    Kansal N; Silakari O; Ravikumar M
    Eur J Med Chem; 2010 Jan; 45(1):393-404. PubMed ID: 19892442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
    Lu A; Zhang J; Yin X; Luo X; Jiang H
    Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase pharmacophore model derived from diverse classes of inhibitors.
    Zhang J; Yu K; Zhu W; Jiang H
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3009-14. PubMed ID: 16530411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
    Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
    J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
    Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
    Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
    Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
    SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
    Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
    Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.
    Equbal T; Silakari O; Rambabu G; Ravikumar M
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1594-600. PubMed ID: 17236767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
    Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.
    Debnath AK
    J Med Chem; 2003 Oct; 46(21):4501-15. PubMed ID: 14521412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
    Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
    Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore identification of Raf-1 kinase inhibitors.
    Zhu T; Jiao Y; Chen YD; Wang X; Li HF; Zhang LY; Lu T
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2346-50. PubMed ID: 18346893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
    Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
    Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
    Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore identification and validation study of CK2 inhibitors using CoMFA/CoMSIA.
    Morshed MN; Muddassar M; Pasha FA; Cho SJ
    Chem Biol Drug Des; 2009 Aug; 74(2):148-58. PubMed ID: 19563463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors.
    Almerico AM; Tutone M; Lauria A
    J Mol Model; 2012 Jul; 18(7):2885-95. PubMed ID: 22127610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
    Foster R; Griffith R; Ferrao P; Ashman L
    J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.